Our Mission
Inclusive and Open to Diversity,
Innovationoriented to Win Together
and Benefit the Mankind

Haihe Biopharma
Pioneering the Future
of Original
Oncology Drugs

Haihe Stories
Our Scientists

Haihe Mission

Our Mission and Purpose

Research and Development

More R&D Pipelines

Haihe Stories

Our Scientists

About Us
  • Established in


  • Headquartered in




  • China





  • Specializing in the Discovery,

    Development, Production

    and Commercialization

    Innovative Oncology


  • Academician1



    Number of


    As of Jan.30,2023

  • Core Products

    in R&D Pipeline


R&D Field
Cancer Types Covered by the R&D Pipeline
Lung Cancer
Breast Cancer
Gastric Cancer
Nasopharyngeal Cancer
Strong, Innovation-driven R&D Capabilities
Rich and Balanced Pipeline
Updated in March 2023
  • 14 Oncology+Non-oncology compounds in core pipeline, including those in late clinical stage and pre-clinical stage
  • The compound targets in the late stage of development have been well-validated
  • Multiple potential best-in-class compounds are expected to be used in combination to treat major indications
Company Milestones

Haihe Biopharma is an innovation-driven biotechnology company in China focusing on the discovery, development, production and commercialization of innovative anti-tumor drugs. Haihe brings life-saving therapies to cancer patients worldwide. 


    March 2022

     NMPA-CDE Grants Priority Review Designation to Haihe Biopharma's Glumetinib


    February 2022

    The NDA for Haihe Biopharma’s Glumetinib has been accepted for review by the CDE.


    January 2022

    U.S. FDA Grants Orphan Drug Designation to Haihe Biopharma’s Glumetinib for Treatment of NSCLC with MET Genomic Aberration


    March 2021

    Haihe established its Japan office


    July 2020

    Haihe completed
    Haihe completed worth
    1.2 billion yuan Series B Funding


    July 2020

    Haihe completed the reorganization of related group companies. Shanghai Haihe Pharmaceutical Research and Development Co Ltd acquired the stakes of Shanghai RMX Biopharma Co Ltd.


    December 2019

    Haihe established its US office


    October 2019

    Haihe’s Manufacturing Hub set foot in Taizhou China Medical City, with planned investment of 600 million yuan


    September 2019

    Haihe was recognized as Shanghai’s New & Hi-Tech Enterprise


    April 2019

    Haihe completed the first patient dosing of oral paclitaxel RMX3001 phase III clinical trial for advanced gastric cancer


    February 2019

    Haihe completed Haihe completed $136.6 million Series A Funding


    January 2019

    The pivotal Phase IIb clinical trial of first-class innovative drug Lucitanib for patients with thymic cancer completed the enrollment of the first patient in China


    September 2018

    Haihe reached strategic cooperation agreements with Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Tigermed, Junshi Biosciences, 3D Medicines, and Jiuzhou Pharmaceutical


    March 2018

    Haihe Pharmaceutical merged with Nuomaixi Pharmaceutical to form Haihe Biopharma Co, Ltd.

I am glad that some research achievements in China in the field of oncology drugs have already been on par with global leaders. Especially in personalized research, China is carrying out projects concurrently with the world, and striving to be a leader in certain aspects.

Academician Jian Ding:
Make Good Drugs that Ordinary People Can Afford

(Xinmin Evening News,2020-11-11)

I often tell myself to work hard and seize every opportunity. I also often inspire my team to develop good drugs that ordinary people can afford, so that new drugs created by Chinese scientists will come onto the global stage as soon as possible.
News Center
Join Us
Let’s ride the wave of developing original innovative drugs in China. Haihe Biopharma aspires to become one of the companies that R&D professionals and outstanding managers have the strongest desire to join.
Follow Us
?2020 Haihe Biopharma Co., Ltd.
All Rights Reserved 滬ICP備12016151號-1